X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs DR. REDDYS LAB - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD DR. REDDYS LAB BIOCON LTD/
DR. REDDYS LAB
 
P/E (TTM) x 91.2 31.5 289.1% View Chart
P/BV x 7.7 3.4 228.6% View Chart
Dividend Yield % 0.1 0.8 19.2%  

Financials

 BIOCON LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
DR. REDDYS LAB
Mar-18
BIOCON LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,1882,788 42.6%   
Low Rs3051,902 16.0%   
Sales per share (Unadj.) Rs68.7860.8 8.0%  
Earnings per share (Unadj.) Rs7.657.1 13.2%  
Cash flow per share (Unadj.) Rs14.0122.0 11.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.10.9 15.7%  
Book value per share (Unadj.) Rs86.3757.7 11.4%  
Shares outstanding (eoy) m600.00165.91 361.6%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x10.92.7 398.7%   
Avg P/E ratio x98.941.1 240.6%  
P/CF ratio (eoy) x53.419.2 278.0%  
Price / Book Value ratio x8.63.1 279.4%  
Dividend payout %13.235.0 37.8%   
Avg Mkt Cap Rs m447,900389,034 115.1%   
No. of employees `0006.123.5 26.1%   
Total wages/salary Rs m9,31132,149 29.0%   
Avg. sales/employee Rs Th6,705.86,070.8 110.5%   
Avg. wages/employee Rs Th1,514.21,366.6 110.8%   
Avg. net profit/employee Rs Th736.9402.5 183.1%   
INCOME DATA
Net Sales Rs m41,234142,810 28.9%  
Other income Rs m2,0621,552 132.9%   
Total revenues Rs m43,296144,362 30.0%   
Gross profit Rs m8,29123,512 35.3%  
Depreciation Rs m3,85110,772 35.8%   
Interest Rs m615788 78.0%   
Profit before tax Rs m5,88713,504 43.6%   
Minority Interest Rs m2130-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5694,380 35.8%   
Profit after tax Rs m4,5319,468 47.9%  
Gross profit margin %20.116.5 122.1%  
Effective tax rate %26.732.4 82.2%   
Net profit margin %11.06.6 165.7%  
BALANCE SHEET DATA
Current assets Rs m41,486104,984 39.5%   
Current liabilities Rs m21,41368,938 31.1%   
Net working cap to sales %48.725.2 192.9%  
Current ratio x1.91.5 127.2%  
Inventory Days Days6474 86.0%  
Debtors Days Days94104 90.9%  
Net fixed assets Rs m50,661104,385 48.5%   
Share capital Rs m3,000830 361.4%   
"Free" reserves Rs m48,808124,886 39.1%   
Net worth Rs m51,808125,716 41.2%   
Long term debt Rs m17,89825,089 71.3%   
Total assets Rs m99,897225,443 44.3%  
Interest coverage x10.618.1 58.3%   
Debt to equity ratio x0.30.2 173.1%  
Sales to assets ratio x0.40.6 65.2%   
Return on assets %5.24.5 113.2%  
Return on equity %8.77.5 116.1%  
Return on capital %9.69.7 99.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05872,623 16.6%   
Fx outflow Rs m7,34818,916 38.8%   
Net fx Rs m4,71053,707 8.8%   
CASH FLOW
From Operations Rs m6,62118,030 36.7%  
From Investments Rs m-6,840-14,883 46.0%  
From Financial Activity Rs m-2,397-4,440 54.0%  
Net Cashflow Rs m-2,612-1,236 211.3%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  ALEMBIC LTD  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Down 1%; Realty, Auto Stocks Tank(12:30 pm)

After opening the day flat share markets in India are trading on a negative note and are presently trading below the dotted line.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

BIOCON LTD share price has hit an all time high at Rs 696 (up 1.4%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.4%) and SANOFI INDIA (up 2.6%). The top losers include TORRENT PHARMA (down 0.1%) and AUROBINDO PHARMA (down 0.2%).

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 24, 2018 01:41 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - LUPIN LTD COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS